Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$4.6m

Galmed Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GLMD?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1630.0108%
Institutions7,3020.485%
Private Companies19,2121.27%
VC/PE Firms167,25811.1%
General Public1,313,06187.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 351.3%.

Top Shareholders

Top 19 shareholders own 12.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.1%
Heights Capital Management, Inc.
167,258US$505.1k4,150%0.07%
1.26%
G. Yarom Medical Research Ltd
18,982US$57.3k0%no data
0.35%
UBS Asset Management AG
5,267US$15.9k22,800%no data
0.11%
Macquarie Investment Management Business Trust
1,700US$5.1k0%no data
0.015%
Tushia Consulting Engineers Ltd
230US$694.50%no data
0.011%
Tower Research Capital Europe Limited
173US$522.50%no data
0.0069%
Morgan Stanley, Investment Banking and Brokerage Investments
104US$314.0-96.6%no data
0.0028%
David Sidransky
42US$127.00%no data
0.0028%
Shmuel Nir
42US$127.00%no data
0.0021%
Yohai Stenzler
31US$93.80%no data
0.0021%
Guy Nehemya
31US$93.80%no data
0.0012%
Wells Fargo & Company, Securities and Brokerage Investments
18US$54.212.5%no data
0.0011%
TSFG, LLC
17US$51.46.25%no data
0.0011%
Doron Cohen
17US$51.40%no data
0.00093%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
14US$42.37.69%no data
0.00033%
Osaic Wealth, Inc. , Asset Management Arm
5US$15.025%no data
0.00013%
Allworth Financial, L.P.
2US$5.9100%no data
0.00007%
BNP Paribas Arbitrage Sa, Asset Management Arm
1US$3.20%no data
0.00007%
Elevation Wealth Partners, LLC
1US$3.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 06:29
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galmed Pharmaceuticals Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.